Attached files
file | filename |
---|---|
EX-99.2 - PRESENTATION - VistaGen Therapeutics, Inc. | ex99-2.htm |
EX-99.1 - PRESS RELEASE - VistaGen Therapeutics, Inc. | ex99-1.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) of the SECURITIES EXCHANGE ACT OF
1934
Date of Report (Date of earliest event reported): July 23, 2020
VistaGen Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
NEVADA
|
000-54014
|
20-5093315
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification Number)
|
343 Allerton Ave.
South San Francisco, California 94090
|
(Address of principal executive offices)
|
(650) 577-3600
(Registrant’s telephone number, including area
code)
Not Applicable
(Former name or former address, if changed since last
report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
☐ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a
-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d -2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e -4(c))
Securities registered pursuant to Section 12(b) of the
Act:
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which
registered
|
Common
Stock, par value $0.001 per share
|
VTGN
|
Nasdaq
Capital Market
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (17
CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934
(17 CFR 240.12b-2)
Emerging Growth Company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange
Act ☐
Item 7.01 Regulation FD Disclosure.
On
July 23, 2020, VistaGen Therapeutics, Inc. (the “Company”) announced the results
of a positive meeting with the U.S. Food and Drug
Administration ("FDA")
regarding Phase 3 development of PH94B for the acute treatment of
anxiety in adult patients with social anxiety disorder ("SAD"), including consensus on key
aspects of a unique initial pivotal Phase 3 clinical trial of PH94B
involving a single-event, laboratory-simulated public speaking
challenge in adult patients with SAD. A copy of the Company’s press release is
attached hereto as Exhibit 99.1.
On July
23, 2020, the Company began utilizing a new corporate presentation,
a copy of which is attached to this Current Report on Form 8-K as
Exhibit 99.2.
The information in Item 7.01 of this Current
Report on Form 8-K, including the information set
forth in Exhibit 99.1 and 99.2, is being furnished and shall
not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, as amended (the
“Exchange
Act”), nor shall Exhibit
99.1 and 99.2 filed herewith be deemed incorporated by reference in
any filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits Index
Exhibit No.
|
|
Description
|
|
|
|
|
Press
Release issued by VistaGen Therapeutics, Inc., dated July 23,
2020.
|
|
99.2 |
|
VistaGen
Therapeutics, Inc. Corporate Presentation, dated Summer
2020.
|
Signatures
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
|
VistaGen
Therapeutics, Inc.
|
|
|
|
|
Date:
July 24, 2020
|
By:
|
/s/ Shawn K. Singh
|
|
|
Shawn
K. Singh
Chief
Executive Officer
|